What drove GSK's Q3 2025 sales growth?

GSK's Q3 2025 sales growth of 7% was driven by strong performance in its Vaccines, Specialty Medicines, and General Medicines divisions.

How did GSK's profitability fare in Q3 2025?

GSK reported an 11% rise in core operating profit and a 14% expansion in core earnings per share (EPS) in Q3 2025.

What changes has GSK made to its 2025 guidance?

GSK has upgraded its 2025 guidance, now expecting core EPS growth of 10-12% and core operating profit growth of 9-11%, up from the previous ranges of 6-8% for both metrics.

Home / Business and Economy / GSK Surges Ahead: Vaccines and Specialty Meds Fuel Impressive Q3 Growth

GSK Surges Ahead: Vaccines and Specialty Meds Fuel Impressive Q3 Growth

13 Nov

•

Summary

GSK reports 7% sales growth in Q3 2025, driven by vaccines, specialty medicines
Core operating profit and EPS rise 11% and 14% respectively
Company upgrades 2025 guidance, expects 9-11% profit and 10-12% EPS growth

GSK Surges Ahead: Vaccines and Specialty Meds Fuel Impressive Q3 Growth

As of November 13, 2025, global healthcare and biopharmaceutical company GSK plc (NYSE:GSK) has reported impressive financial results for the third quarter of the year. The company's total sales for the quarter reached £8.5 billion, up 7% on an actual exchange rate (AER) basis and 8% on a constant exchange rate (CER) basis. This growth was primarily driven by strong performance in the company's Vaccines, Specialty Medicines, and General Medicines divisions.

Sales in the Specialty Medicines segment rose 16% to £3.4 billion, while Respiratory, Immunology & Inflammation sales grew 15% to £1.0 billion. Oncology and HIV sales also experienced significant increases of 39% and 12%, respectively. Vaccine sales in Q3 2025 increased 2% to £2.7 billion.